Compare Regeneron Pharmaceuticals Inc (REGN) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.68. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals.
| REGN | XDTE | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $812.27 | $44.76 |
52-Week Low | $545.46 | $36.00 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
XDTE trades at $38.44, down 0.1% on the day, with technical indicators showing a bearish trend. The ETF generates frequent dividend payouts but faces scrutiny over sustainability. Recent news highlights concerns about yield calculations and NAV erosion despite high distribution frequency.
The outlook remains cautious due to structural risks in the covered call strategy and declining NAV. Investors face trade-offs between high income potential and capital depreciation risks in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
